Barely Significant
← all excerpts

Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer.

Cancers (Basel) · 2021 · PMC7865814 · PMID 33572705

Europe PMCDOI
1
hedged sentence
0.0451
closest p · 0.9× alpha
0.0451
boldest claim

The sentences

did not reach statistical significancep = 0.0451actually significant
On the other hand, the tremelimumab arm did not reach statistical significance with median OS of 10.4 months vs. 10.5 months with chemotherapy alone (HR 0.82, 95% CI 0.68–1.00, p = 0.0451).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.